Literature DB >> 10390253

Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT).

B Law1, C Fitzsimon, L Ford-Jones, J McCormick, M Rivière.   

Abstract

OBJECTIVE: Primarily, to determine the direct medical costs and productivity losses associated with complicated chickenpox (hospitalized cases) and, secondarily, to quantify the overall economic burden of chickenpox in Canada.
METHODS: Direct medical resource consumption patterns were determined by chart review of 160 otherwise healthy children and 40 children with leukemia hospitalized for chickenpox. Children were selected from the database of the Immunization Monitoring Program Active (IMPACT), a network of 11 tertiary-care hospitals in Canada that collected information at the time of hospitalization from January 1991 to March 1996. An additional 26 healthy children hospitalized were recruited prospectively by IMPACT. Productivity losses (time lost from work and daily activities) were assessed by caregiver interviews. Treatment costs were determined from the patient, Ministry of Health, and societal perspectives.
RESULTS: The average societal per case cost for complicated chickenpox in healthy children was $7060 and $8398, respectively, from the retrospective and prospective assessments. For children with leukemia, the direct medical cost was estimated at $7228. These costs were combined with a cost established previously for uncomplicated chickenpox. The estimated yearly overall economic impact of chickenpox in Canada was $122.4 million, with $24.0 million attributable to Ministry of Health costs, assuming an estimated yearly incidence of 346 527 cases and a 0.54% rate of hospitalization for healthy children.
CONCLUSIONS: Direct medical costs are the major cost driver in the care of complicated chickenpox. However, in the context of the overall economic burden of the disease, uncomplicated chickenpox is the major cost driver, contributing 89% to the total cost.

Entities:  

Mesh:

Year:  1999        PMID: 10390253     DOI: 10.1542/peds.104.1.7

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  16 in total

1.  School based screening for hypothyroidism in Down's syndrome by dried blood spot TSH measurement.

Authors:  S E Noble; K Leyland; C A Findlay; C E Clark; J Redfern; J M Mackenzie; R W Girdwood; M D Donaldson
Journal:  Arch Dis Child       Date:  2000-01       Impact factor: 3.791

Review 2.  25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.

Authors:  M Takahashi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Chickenpox vaccination, not chickenpox, should be routine for Canadian children.

Authors:  B J Law
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

Review 4.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Canada's first universal varicella immunization program: Lessons from Prince Edward Island.

Authors:  Lamont Sweet; Peggy Gallant; Marie Morris; Scott A Halperin
Journal:  Can J Infect Dis       Date:  2003-01

6.  Varicella vaccine for children.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-07       Impact factor: 2.253

7.  Epidemiological Study on the Incidence of Herpes Zoster in Nearby Cheonan.

Authors:  Ho Soon Jung; Jin Ku Kang; Sie Hyeon Yoo
Journal:  Korean J Pain       Date:  2015-07-01

8.  Three-year follow-up of protection rates in children given varicella vaccine.

Authors:  David W Scheifele; Scott A Halperin; Francisco Diaz-Mitoma
Journal:  Can J Infect Dis       Date:  2002-11

9.  Burden of chickenpox on families: A study in Quebec.

Authors:  P De Wals; M Blackburn; M Guay; G Bravo; D Blanchette; M Douville-Fradet
Journal:  Can J Infect Dis       Date:  2001-01

10.  Severe complications associated with varicella: Province of Quebec, April 1994 to March 1996.

Authors:  P Rivest; L Bédard; L Valiquette; E Mills; M H Lebel; G Lavoie; J Carsley
Journal:  Can J Infect Dis       Date:  2001-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.